18 F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

Matthijs H. van Gool,Tjeerd S. Aukema,Eva E. Schaake,Herman Rijna,Henk Codrington,Renato A. Valdés Olmos,Hendrik J. Teertstra,Renée van Pel,Sjaak Burgers,Harm van Tinteren,Houke M. Klomp

18 F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

2014

Matthijs H. van Gool
Tjeerd S. Aukema
Eva E. Schaake
Herman Rijna
Henk Codrington
Renato A. Valdés Olmos
Hendrik J. Teertstra
Renée van Pel
Sjaak Burgers
Harm van Tinteren
Houke M. Klomp

Purpose To prospectively evaluate diagnostic computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for identification of histopathologic response to neoadjuvant erlotinib, an epidermal growth factor receptor–tyrosine kinase inhibitor in patients with resectable non-small cell lung cancer (NSCLC).

Keywords:

Pathology
Positron emission tomography
Radiology
Epidermal growth factor
Erlotinib
Epidermal growth factor receptor
Computed tomography
Tyrosine-kinase inhibitor
Lung cancer
Fluorodeoxyglucose
Medicine
non small cell
Kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations